CRISPR

CRISPR1-glo1

ID

ZDB-CRISPR-191021-1

Name

CRISPR1-glo1

Previous Names

None

Target

glo1 (1)

Sequence

5' - GGACGTTCTCCCGTAGAG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf3029	glo1

Expression

Gene expression in Wild Types + CRISPR1-glo1

No data available

Phenotype

Phenotype resulting from CRISPR1-glo1

No data available

Phenotype of all Fish created by or utilizing CRISPR1-glo1

Phenotype	Fish	Conditions	Figures
whole organism aldh3a1 expression increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. S3 from Lodd et al., 2019
fatty acid metabolic process process quality, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 4 from Lodd et al., 2019
whole organism aldh9a1a.2 expression increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. S3 from Lodd et al., 2019
whole organism saturated fatty acid increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 4 from Lodd et al., 2019
whole organism aldh9a1b expression increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. S3 from Lodd et al., 2019
blood glucose increased amount, abnormal	glo1^{zf3029/zf3029}	increased food availability	Fig. 6 from Lodd et al., 2019
liver fatty, abnormal	glo1^{zf3029/zf3029}	increased food availability	Fig. 6 from Lodd et al., 2019
whole organism increased weight, abnormal	glo1^{zf3029/zf3029}	increased food availability	Fig. 6 from Lodd et al., 2019
whole organism aldh3a2a expression increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. S3 from Lodd et al., 2019
skeletal muscle ab6-rps6k labeling increased amount, abnormal	glo1^{zf3029/zf3029}	food availability	Fig. 9 from Lodd et al., 2019
whole organism lactoylglutathione lyase activity arrested, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 1 from Lodd et al., 2019
liver ab6-rps6k labeling increased amount, abnormal	glo1^{zf3029/zf3029}	food availability	Fig. 9 from Lodd et al., 2019
blood glucose increased amount, abnormal	glo1^{zf3029/zf3029}	food availability	Fig. 5 from Lodd et al., 2019
eye methylglyoxal increased amount, abnormal	glo1^{zf3029/zf3029}	food availability	Fig. 8 from Lodd et al., 2019
whole organism glo1 expression absent, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 1 from Lodd et al., 2019
liver ab6-rps6k labeling decreased amount, abnormal	glo1^{zf3029/zf3029}	increased food availability	Fig. 9 from Lodd et al., 2019
whole organism methylglyoxal increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 1, Fig. 5 from Lodd et al., 2019
glucose metabolic process delayed, abnormal	glo1^{zf3029/zf3029}	food availability	Fig. 5 from Lodd et al., 2019
whole organism omega-9 fatty acid increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 4 from Lodd et al., 2019
liver lipid droplet increased amount, abnormal	glo1^{zf3029/zf3029}	increased food availability	Fig. 6 from Lodd et al., 2019
whole organism omega-3 fatty acid increased amount, abnormal	glo1^{zf3029/zf3029}	standard conditions	Fig. 4 from Lodd et al., 2019
intersegmental vessel morphology, abnormal	glo1^{zf3029/zf3029}; y1Tg	chemical treatment: methylglyoxal	Fig. 2 from Lodd et al., 2019
blood vessel morphology, abnormal	glo1^{zf3029/zf3029}; y1Tg	chemical treatment: methylglyoxal	Fig. 2 from Lodd et al., 2019
blood vessel increased branchiness, abnormal	glo1^{zf3029/zf3029}; y1Tg	chemical treatment: methylglyoxal	Fig. 2 from Lodd et al., 2019
retina ocular blood vessel increased amount, abnormal	glo1^{zf3029/zf3029}; y1Tg	increased food availability	Fig. 7 from Lodd et al., 2019

Citations